Amyloid β-peptide in patients with Alzheimer’s disease (AD) has been shown to downregulate the functional activity of glutamate transporters [165]; however, in a more recent study, it was reported to increase the cell surface expression of GLAST protein and boost its ability to uptake glutamate [166]. This evidence concerns the gene SLC1A3 and Alzheimer disease.